Elan (Alzheimers Immunotherapy Program) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Elan (Alzheimers Immunotherapy Program) General Information

Description

Alzheimers Immunotherapy Program is researching, developing and commercializing selective products for the treatment of Alzheimer's Disease. This includes bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's Disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Discovery Tools (Healthcare)
Primary Office
  • Treasury Building, Lower Grand Canal Street
  • Dublin 2
  • Ireland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Elan (Alzheimers Immunotherapy Program) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Elan (Alzheimers Immunotherapy Program)‘s full profile, request access.

Request a free trial

Elan (Alzheimers Immunotherapy Program) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Elan (Alzheimers Immunotherapy Program)‘s full profile, request access.

Request a free trial